

VIDAS® B·R·A·H·M·S PCT™ INTERPRETATION OF RESULTS

**S
E
P
S
I
S**

1 EVALUATE
Assess sepsis risk & severity

> 2.0 ng/mL	High risk for progression to severe sepsis and/or septic shock
0.5–2.0 ng/mL	Sepsis should be considered
< 0.5 ng/mL	Low risk for progression to severe sepsis and/or septic shock

2 MONITOR
Assess risk over time

Test follow-up samples once every 1-2 days, based upon physician discretion, to support decision to discontinue antibiotic therapy.

3 DISCONTINUE
Assess when to discontinue antibiotics

≤ 0.5 ng/mL or ΔPCT > 80%	Discontinuation of antibiotics is encouraged
---------------------------------	--

**L
R
T
I***

1 EVALUATE
Determine if antibiotics are necessary

< 0.1 ng/mL	Antibiotics are strongly discouraged
0.1-0.25 ng/mL	Antibiotics are discouraged
0.26–0.5 ng/mL	Antibiotics are encouraged
> 0.5 ng/mL	Antibiotics are strongly encouraged

2 MONITOR
Assess therapy effectiveness over time

Test follow-up samples once every 1-2 days, based upon physician discretion, to support decision to discontinue antibiotic therapy.

3 DISCONTINUE
Assess when to discontinue antibiotics

≤ 0.25 ng/mL or ΔPCT > 80%	Discontinuation of antibiotics is encouraged
----------------------------------	--

Antibiotic therapy should be considered regardless of PCT result if the patient is clinically unstable, is at high risk for adverse outcome, has strong evidence of bacterial pathogen, or the clinical context indicates antibiotic therapy is warranted.

*Lower Respiratory Tract Infection

Reference: VIDAS B·R·A·H·M·S PCT Package Insert

©2018 bioMérieux, Inc. • BIOMÉRIEUX and the BIOMÉRIEUX logo and VIDAS are used pending and/or registered trademarks belonging to bioMérieux, or one of its subsidiaries, or one of its companies. • Patents: www.biomerieux-usa.com/patents • B·R·A·H·M·S PCT™ is the property of Thermo Fisher Scientific, Inc. and its subsidiaries. 100 Rodolphe Street • Durham, NC 27712 • USA • PRN18-0422-00